Securities Code: 300323 Securities Abbreviation: Huacan Optoelectronics Announcement Number: 2026-016
BOE Huacan Optoelectronics Co., Ltd. Announcement on Application for Comprehensive Credit Line by the Company and its Subsidiaries and Provision of Guarantees for Subsidiaries for 2026
The Company and the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed herein, and are not aware of any false representations, misleading statements, or material omissions.
BOE Huacan Optoelectronics Co., Ltd. (hereinafter referred to as the "Company") held the 18th meeting of the Sixth Board of Directors on March 20, 2026, and approved the "Proposal on the Application for Comprehensive Credit Line by the Company and its Subsidiaries and Provision of Guarantees for Subsidiaries for 2026". This matter is subject to shareholder approval. The relevant situation is hereby announced as follows:
I. Basic Situation of Application for Comprehensive Credit Line and Guarantee for 2026
(I) Basic Situation of Application for Comprehensive Credit Line
To meet the funding needs of the Company's daily operations and business development, and to ensure the smooth progress of the Company's business in 2026, the Company and its wholly-owned subsidiaries (hereinafter referred to as "subsidiaries", which are all subsidiaries within the scope of consolidated financial statements) plan to apply for a comprehensive credit line from financial institutions such as China Development Bank, Export-Import Bank of China, Bank of China, Agricultural Bank of China, Industrial and Commercial Bank of China, China Construction Bank, Bank of Communications, China Merchants Bank, Shanghai Pudong Development Bank, China Everbright Bank, China Guangfa Bank, Industrial Bank, China Minsheng Bank, Ping An Bank, Bank of Beijing, Bank of Suzhou, Bank of Ningbo, China Everbright Bank, Zheshang Bank, China CITIC Bank, Nanjing Bank, etc., with a total credit line not exceeding RMB 5.5 billion. The scope of comprehensive credit includes, but is not limited to, working capital loans, project loans, letters of credit, bank acceptance bills, bank guarantees, accounts receivable trade financing, ultra-short-term bonds, and other comprehensive credit businesses (specific business types are subject to actual approval).
The specific credit line, loan interest rate, fee standards, credit period, etc., will be subject to the final negotiated and signed credit agreement between the Company and the financial institutions; the specific financing amount will be determined based on the actual demand for operating funds of the Company and its subsidiaries.
(II) Overview of Guarantee Forecast
To meet the business development needs of the subsidiaries and ensure their operating capital requirements, the Company plans to provide corresponding guarantees for the bank's comprehensive credit line applied for by the subsidiaries in 2026, with an estimated new guarantee amount not exceeding RMB 1.5 billion. The actual guarantee period and amount will be determined according to the principal loan agreement. Guarantee methods include, but are not limited to, joint and several liability guarantees, pledge of equity in subsidiaries, and mortgage of other assets.
The credit line and guarantee forecast applied for this time is authorized for a period of twelve months from the date of approval by the 2025 Annual General Meeting of Shareholders. The Company may adjust the credit and guarantee limits among subsidiaries with an asset-liability ratio below 70% (including newly established or acquired subsidiaries) based on actual operating needs. Within this credit line and authorization period, the Company will no longer submit each credit and guarantee matter for separate approval by the Board of Directors and the Shareholders' Meeting. The Board of Directors hereby requests the Shareholders' Meeting to authorize the Company's Chairman or his authorized representative to sign relevant legal documents with banks on behalf of the Company and its subsidiaries and handle related procedures, with the authorization period being the same as the validity period of the resolution.